| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Protein disulfide-isomerase A2;5.3.4.1;Pancreas-specific protein disulfide isomerase;PDIp;PDIA2;PDIP; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Form | Liquid |
| Host | |
| Immunogen | A synthesized peptide derived from human IL32 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Storage | |
| Target | |
| UniProt # |
Overview
This product is an anti-IL32 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone 25I76; isotype IgG; reactivity: Human. Reported application contexts include WB (as provided in the source record). Boster Bio Anti-IL32 Rabbit Monoclonal Antibody catalog # M03286-1. Tested in WB application. This antibody reacts with Human.
Key elements and design rationale
- Target: IL32 (Protein disulfide-isomerase A2).
- Antibody format: Monoclonal; clone 25I76; isotype IgG.
- Host: Rabbit.
- Species reactivity: Human (confirm in your model system with appropriate controls).
This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.
Biological background
IL32 (protein: T-cell surface glycoprotein CD3 zeta chain) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Acts as an intracellular estrogen-binding protein. May be involved in modulating cellular levels and biological functions of estrogens in the pancreas. May act as a chaperone that inhibits aggregation of misfolded proteins. . Reported cellular localization context: Endoplasmic reticulum lumen . Tissue expression notes (as provided): Highly expressed in pancreas (at protein level). .
Research relevance and current trends
- Research context keywords from the source record include: MAPK Pathway,Protein Phosphorylation,Ser/Thr Kinases,Signal Transduction,Tyrosine Kinases.
- Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
- Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.
Common research applications
- Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
Workflow ideas (metafield): Validate IL32 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect IL32 expression by Western blot in cell or tissue lysates, Compare relative IL32 levels across experimental conditions (dose/time-course) using antibody-based readouts
Notes for experimental interpretation
- Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
- Apparent molecular weight may vary by sample type and processing (observed MW: 23 kDa; calculated MW: 58206 MW).
- Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.
Additional product details (from the source record)
- Molecular weight (observed): 23 kDa
- Cellular localization (provided): Endoplasmic reticulum lumen .
- Tissue details (provided): Highly expressed in pancreas (at protein level). .
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
